Abstract
Risperidone (R 64766) was administered during 4 weeks in increasing doses to 17 psychotic patients, to evaluate the hematological and cardiovascular safety, the therapeutic effect, side effects, effects upon endocrinological parameters and the pharmacokinetic profile. Following a placebo wash-out period of 1 week, the initial dose was 10 mg daily, increasing with 5 mg per week until the maximal dose of 25 mg daily was reached during the 4th week of treatment. Doses up to 20 mg daily resulted in a significant improvement of the total BPRS score and of the different BPRS factor scores; with higher doses, no further clinical benefit was achieved except for the hostility and anxietydepression factor, while sedation became more prominent. No increase of extrapyramidal symptoms wasnoticed. Except for the sedation observed with higher doses, risperidone was well tolerated. No clinically relevant effects on cardiovascular and ECG parameters were noticed, and except for a slight increase of aspartate aminotransferase and alanine aminotransferase in one patient, no laboratory abnormalities were observed. Prolactin showed an expected increase, while the other endocrinological parameters revealed no changes. Risperidone had a linear pharmacokinetic profile.
Similar content being viewed by others
References
American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders (edn III) Washington DC
Ansoms L, De Backer-Dierick G, Vereecken JLTM (1977) Sleep disorders in patients with severe mental depression: doubleblind placebo-controlled evaluation of the value of pipamperone. Acta Psychiatr Scand 55:116–122
Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ (1988) The pharmacological profile of ritanserin, a very specific central serotonin-S2 antagonist. Drug Dev Res 15:61–73
Castelao JF, Ferreira F (1989) Risperidone (R 64766) in the treatment of therapy-resistant chronic psychotic patients: an open dose-finding study. Schizophr Res (in press)
Ceulemans DLS, Gelders YG, Hoppenbrouwers M-LJA, Reyntjens AJM Janssen PAJ (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85:329–332
Deberdt R (1976) Pipamperone in the treatment of behaviour disorders. A large scale multicentre evaluation. Acta Psychiatr Belg 76:157–166
Janssen PAJ, Niemegeers CJE, Awouters FHL, Schellekens KHL, Megens AAHP, Meert TP (1988) Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693
Leysen JE, Gommeren W, Van Gompel P, Wijnants J, Janssen PFM, Laduron PM (1985) Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long-acting serotonin-S2 antagonist. Mol Pharmacol 27:600–611
Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661–670
Meert TF, de Haes P, Niemegeers CJE (1989) Risperidone (R 64766), a potent and complete LSD-antagonist in drug discrimination by rats. Psychopharmacology 97:206–212
Megens AAHP, Awouters FHL, Niemegeers CJE (1988) Differential effects of the new antipsychotic risperidone on large and small motor movements in rats. Psychopharmacology 95: 493–496
Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812
Reyntjens AJM, Gelders YG, Hoppenbrouwers M-LJA, Vanden Bussche G (1986) Thymostenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8:205–211
Roose K, Gelders YG, Heylen SLE (1989) Risperidone (R 64766) in psychotic patients: a first clinical therapeutic exploration. Acta Psychiatr Belg (in press)
Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 212:11–19
Van Putten T, Marder SR, Mintz J (1987) The therapeutic index of haloperidol in newly admitted schizophrenic patients. Psychopharm Bull 23:201–205
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mesotten, F., Suy, E., Pietquin, M. et al. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 99, 445–449 (1989). https://doi.org/10.1007/BF00589890
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00589890